OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
LeadF
Forbion
Activity from announced rounds
Activity in this selectionSeries C+
Forbion is an investment firm whose official portfolio and financing news identify CellCentric, Sling and Solstice.
Recorded funding activity
Sling develops an oral medicine for thyroid eye disease. Solstice advances an engineered cancer-immunotherapy antibody, while RQ Bio develops preventive antibodies for vulnerable patients facing influenza. These are separate clinical programs and company financings.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- 2 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $653M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionSling Therapeutics, Inc.
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
$123MSeries C
LeadCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosed